Nemucore Publishes Research Article, "Nanoemulsions in Translational Research"

WORCESTER, Mass. - March 12, 2014 - PRLog -- Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the publication in American Association of Pharmaceuticals Scientist’s (AAPS) peer reviewed online journal AAPS PharmSciTech of a research article titled “Nanoemulsions in Translational Research – Opportunities and Challenges in Targeted Cancer Therapy.”  The article was co-authored by Tim Coleman.

Nanoemulsion dosage serves as a vehicle for the delivery of active pharmaceutical ingredients and has attracted great attention in drug delivery and pharmacotherapy.  In particular, nanoemulsions act as an excellent vehicle for poorly aqueous soluble drugs, which are otherwise difficult to formulate in conventional dosage forms.  Particle size at the nanoscale and larger surface area lead to some very interesting physical properties that can be exploited to overcome anatomical and physiological barriers associated with drug delivery to complex diseases such as cancer.  Attributes such as size, surface charge, prolonged blood circulation, target specific binding ability and imaging capability can be tuned to assist in delivering drug/imaging agents to the specific site of interest, based on active and passive targeting mechanisms.

“Our work on nanoemulsions provides strong evidence that clinically relevant nanomedicines can be designed using this platform.  Additionally the critical quality attributes associated with manufacturing nanoemulsions are robust and can be documented consistent with the FDA’s Quality by Design initiative. ” said Tim Coleman.  “Because of Nemucore’s significant understanding of key process variables we can design our nanomedicines with attributes for easier translation of dosage forms for clinical use.”

Nemucore is currently working towards bringing cancer-combatting nanomedicines to the clinic.

About Nemucore Medical Innovations, Inc.

NMI is dedicated to designing, investigating, developing and commercializing life-saving novel nanomedicines for the treatment of ovarian cancer and other unmet medical needs.  Ultimately, NMI’s products will be part of the personalized medicine revolution occurring in cancer therapies.  Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic.  As a participant in the National Cancer Institute’s Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and the emerging biopharmaceutical community.  NMI was founded in 2008 and is based in Worcester, Massachusetts.  For more information, please visit http://www.nemucore.com.

Forward-looking Statements Make sure this is the correct FLS

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements.  The Company anticipates that subsequent events and developments will cause the Company’s views to change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.